Tom Van Herpe
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Tom Van Herpe has a total of 44 co-authors. Here are the top co-authors by number of shared publications:
- Greet Van Den Berghe
Laboratory of Intensive Care Medicine, Department of Cellular and Molecular Medicine, KU Leuven, Leuven, Belgium
13 shared publications Bart De Moor
Department of Electrical Engineering (ESAT) Katholieke Universiteit Leuven Research Division SCD iMINDS Medical Information Technologies Leuven (Heverlee), Belgium
7 shared publications- Bart De Moor
KU Leuven
4 shared publications Dieter Mesotten
Department of Intensive Care Medicine Katholieke Universiteit Leuven University Hospitals Leuven Leuven, Belgium
4 shared publications- Bert Pluymers
Katholieke Universiteit Leuven, Department of Electrical Engineering (ESAT), SCD-SISTA, Kasteelpark Arenberg 10, B-3001 Leuven (Heverlee), Belgium
2 shared publications - Dieter Mesotten
11Department of Intensive Care Medicine, University Hospitals Leuven, Herestraat 49, Leuven B-3000, Belgium
2 shared publications
Latest Publications
- Open Access
- 1 April 2015
- Published by Oxford University Press (OUP) in Clinical Chemistry
- Vol. 61 (4) , 666-667
In Reply
We thank Dr. Krouwer for his constructive suggestions regarding the total error modeling strategy as recently presented in Van Herpe et al. (1). We agree that,
- 1 April 2015
- Published by Oxford University Press (OUP) in Clinical Chemistry
- Vol. 61 (4) , 666-667
Open AccessIn Reply
We thank Dr. Krouwer for his constructive suggestions regarding the total error modeling strategy as recently presented in Van Herpe et al. (1). We agree that,
- 1 December 2014
- Published by Oxford University Press (OUP) in Clinical Chemistry
- Vol. 60 (12) , 1510-1518
Modeling of Effect of Glucose Sensor Errors on Insulin Dosage and Glucose Bolus Computed by LOGIC-Insulin
Background: Effective and safe glycemic control in critically ill patients requires accurate glucose sensors and adequate insulin dosage calculators. The LOGIC-Insulin calculator for glycemic control has recently been validated in the LOGIC-1 randomized controlled trial. In this study, we aimed to determine the allowable error for intermittent and continuous glucose sensors, on the basis of the LOGIC-Insulin calculator. Methods: A gaussian simulation model with a varying bias (0%–20%) and CV (−20% to +20%) simulated blood glucose values from the LOGIC-1 study (n = 149 patients) in 10 Monte Carlo steps. A clinical error grid system was developed to compare the simulated LOGIC-Insulin–directed intervention with the nominal intervention (0% bias, 0% CV). The severity of error measuring the clinical effect of the simulated LOGIC-Insulin intervention was graded as type B, C, and D errors. Type D errors were classified as acutely life-threatening (0% probability preferred). Results: The probability of all types of errors was lower for continuous sensors compared with intermittent sensors. The maximum total error (TE), defined as the first TE introducing a type B/C/D error, was similar for both sensor types. To avoid type D errors, TEs Conclusions: Continuous sensors had a lower probability for clinical errors than intermittent sensors at the same accuracy level. These simulations demonstrated the suitability of the LOGIC-Insulin control system for use with continuous, as well as intermittent, sensors.
- 1 December 2014
- Published by Oxford University Press (OUP) in Clinical Chemistry
- Vol. 60 (12) , 1510-1518
Modeling of Effect of Glucose Sensor Errors on Insulin Dosage and Glucose Bolus Computed by LOGIC-Insulin
Background: Effective and safe glycemic control in critically ill patients requires accurate glucose sensors and adequate insulin dosage calculators. The LOGIC-Insulin calculator for glycemic control has recently been validated in the LOGIC-1 randomized controlled trial. In this study, we aimed to determine the allowable error for intermittent and continuous glucose sensors, on the basis of the LOGIC-Insulin calculator. Methods: A gaussian simulation model with a varying bias (0%–20%) and CV (−20% to +20%) simulated blood glucose values from the LOGIC-1 study (n = 149 patients) in 10 Monte Carlo steps. A clinical error grid system was developed to compare the simulated LOGIC-Insulin–directed intervention with the nominal intervention (0% bias, 0% CV). The severity of error measuring the clinical effect of the simulated LOGIC-Insulin intervention was graded as type B, C, and D errors. Type D errors were classified as acutely life-threatening (0% probability preferred). Results: The probability of all types of errors was lower for continuous sensors compared with intermittent sensors. The maximum total error (TE), defined as the first TE introducing a type B/C/D error, was similar for both sensor types. To avoid type D errors, TEs Conclusions: Continuous sensors had a lower probability for clinical errors than intermittent sensors at the same accuracy level. These simulations demonstrated the suitability of the LOGIC-Insulin control system for use with continuous, as well as intermittent, sensors.
- Open Access
- 13 June 2014
- Published by Springer Nature in Critical Care
- Vol. 18 (3) , 226
Continuous glucose control in the ICU: report of a 2013 round table meeting
Achieving adequate glucose control in critically ill patients is a complex but important part of optimal patient management. Until relatively recently, intermittent measurements of blood glucose have been the only means of monitoring blood glucose levels. With growing interest in the possible beneficial effects of continuous over intermittent monitoring and the development of several continuous glucose monitoring (CGM) systems, a round table conference was convened to discuss and, where possible, reach consensus on the various aspects related to glucose monitoring and management using these systems. In this report, we discuss the advantages and limitations of the different types of devices available, the potential advantages of continuous over intermittent testing, the relative importance of trend and point accuracy, the standards necessary for reporting results in clinical trials and for recognition by official bodies, and the changes that may be needed in current glucose management protocols as a result of a move towards increased use of CGM. We close with a list of the research priorities in this field, which will be necessary if CGM is to become a routine part of daily practice in the management of critically ill patients.
- 13 June 2014
- Published by Springer Nature in Critical Care
- Vol. 18 (3) , 226
Open AccessContinuous glucose control in the ICU: report of a 2013 round table meeting
Achieving adequate glucose control in critically ill patients is a complex but important part of optimal patient management. Until relatively recently, intermittent measurements of blood glucose have been the only means of monitoring blood glucose levels. With growing interest in the possible beneficial effects of continuous over intermittent monitoring and the development of several continuous glucose monitoring (CGM) systems, a round table conference was convened to discuss and, where possible, reach consensus on the various aspects related to glucose monitoring and management using these systems. In this report, we discuss the advantages and limitations of the different types of devices available, the potential advantages of continuous over intermittent testing, the relative importance of trend and point accuracy, the standards necessary for reporting results in clinical trials and for recognition by official bodies, and the changes that may be needed in current glucose management protocols as a result of a move towards increased use of CGM. We close with a list of the research priorities in this field, which will be necessary if CGM is to become a routine part of daily practice in the management of critically ill patients.
- Open Access
- 14 June 2013
- Published by Springer Nature in Critical Care
- Vol. 17 (3) , 229-13
Clinical review: Consensus recommendations on measurement of blood glucose and reporting glycemic control in critically ill adults
The management reporting and assessment of glycemic control lacks standardization. The use of different methods to measure the blood glucose concentration and to report the performance of insulin treatment yields major disparities and complicates the interpretation and comparison of clinical trials. We convened a meeting of 16 experts plus invited observers from industry to discuss and where possible reach consensus on the most appropriate methods to measure and monitor blood glucose in critically ill patients and on how glycemic control should be assessed and reported. Where consensus could not be reached, recommendations on further research and data needed to reach consensus in the future were suggested. Recognizing their clear conflict of interest, industry observers played no role in developing the consensus or recommendations from the meeting. Consensus recommendations were agreed for the measurement and reporting of glycemic control in clinical trials and for the measurement of blood glucose in clinical practice. Recommendations covered the following areas: How should we measure and report glucose control when intermittent blood glucose measurements are used? What are the appropriate performance standards for intermittent blood glucose monitors in the ICU? Continuous or automated intermittent glucose monitoring - methods and technology: can we use the same measures for assessment of glucose control with continuous and intermittent monitoring? What is acceptable performance for continuous glucose monitoring systems? If implemented, these recommendations have the potential to minimize the discrepancies in the conduct and reporting of clinical trials and to improve glucose control in clinical practice. Furthermore, to be fit for use, glucose meters and continuous monitoring systems must match their performance to fit the needs of patients and clinicians in the intensive care setting. See related commentary by Soto-Rivera and Agus, http://ccforum.com/content/17/3/155
- 14 June 2013
- Published by Springer Nature in Critical Care
- Vol. 17 (3) , 229-13
Open AccessClinical review: Consensus recommendations on measurement of blood glucose and reporting glycemic control in critically ill adults
The management reporting and assessment of glycemic control lacks standardization. The use of different methods to measure the blood glucose concentration and to report the performance of insulin treatment yields major disparities and complicates the interpretation and comparison of clinical trials. We convened a meeting of 16 experts plus invited observers from industry to discuss and where possible reach consensus on the most appropriate methods to measure and monitor blood glucose in critically ill patients and on how glycemic control should be assessed and reported. Where consensus could not be reached, recommendations on further research and data needed to reach consensus in the future were suggested. Recognizing their clear conflict of interest, industry observers played no role in developing the consensus or recommendations from the meeting. Consensus recommendations were agreed for the measurement and reporting of glycemic control in clinical trials and for the measurement of blood glucose in clinical practice. Recommendations covered the following areas: How should we measure and report glucose control when intermittent blood glucose measurements are used? What are the appropriate performance standards for intermittent blood glucose monitors in the ICU? Continuous or automated intermittent glucose monitoring - methods and technology: can we use the same measures for assessment of glucose control with continuous and intermittent monitoring? What is acceptable performance for continuous glucose monitoring systems? If implemented, these recommendations have the potential to minimize the discrepancies in the conduct and reporting of clinical trials and to improve glucose control in clinical practice. Furthermore, to be fit for use, glucose meters and continuous monitoring systems must match their performance to fit the needs of patients and clinicians in the intensive care setting. See related commentary by Soto-Rivera and Agus, http://ccforum.com/content/17/3/155
- Open Access
- 1 January 2012
- Published by SAGE Publications in Journal of Diabetes Science and Technology
- Vol. 6 (1) , 15-21
Glycemic Control in the Pediatric Intensive Care Unit of Leuven: Two Years of Experience
Stress hyperglycemia and hypoglycemia are associated with increased mortality and morbidity in critically ill patients. Three randomized controlled trials, in the surgical, medical, and pediatric intensive care unit (PICU) of the Leuven University in Belgium, demonstrated the beneficial response of tightly controlling blood glucose levels within age-adjusted narrow limits by applying intensive insulin therapy. Follow-up studies could not confirm the results obtained in the Leuven studies but revealed the complexity associated with tight glycemic control (TGC). This article gives an overview of the methodological aspects typical of the Leuven TGC concept, with the focus on the PICU. Differences between the adult and the PICU are described. This overview article might help other ICUs by addressing potential differences in clinical practice when implementing TGC.
- 1 January 2012
- Published by SAGE Publications in Journal of Diabetes Science and Technology
- Vol. 6 (1) , 15-21
Open AccessGlycemic Control in the Pediatric Intensive Care Unit of Leuven: Two Years of Experience
Stress hyperglycemia and hypoglycemia are associated with increased mortality and morbidity in critically ill patients. Three randomized controlled trials, in the surgical, medical, and pediatric intensive care unit (PICU) of the Leuven University in Belgium, demonstrated the beneficial response of tightly controlling blood glucose levels within age-adjusted narrow limits by applying intensive insulin therapy. Follow-up studies could not confirm the results obtained in the Leuven studies but revealed the complexity associated with tight glycemic control (TGC). This article gives an overview of the methodological aspects typical of the Leuven TGC concept, with the focus on the PICU. Differences between the adult and the PICU are described. This overview article might help other ICUs by addressing potential differences in clinical practice when implementing TGC.
- Open Access
- 1 March 2011
- Published by SAGE Publications in Journal of Diabetes Science and Technology
- Vol. 5 (2) , 353-357
Assessment of Blood Glucose Control in the Pediatric Intensive Care Unit: Extension of the Glycemic Penalty Index toward Children and Infants
Background: The glycemic penalty index (GPI) is a measure to assess blood glucose (BG) control in critically ill adult patients but needs to be adapted for children and infants. Method: The squared differences between a clinical expertise penalty function and the corresponding polynomial function are minimized for optimization purposes. The average of all penalties (individually assigned to all BG readings) represents the patient-specific GPI. Results: Penalization in the hypoglycemic range is more severe than in the hyperglycemic range as the developing brains of infants and children may be more vulnerable to hypoglycemia. Similarly, hypoglycemia is also more heavily penalized in infants than in children. Conclusions: Extending the adult GPI toward the age-specific GPI is an important methodological step. Long-term clinical studies are needed to determine the clinically acceptable GPI cut-off level.
- 1 March 2011
- Published by SAGE Publications in Journal of Diabetes Science and Technology
- Vol. 5 (2) , 353-357
Open AccessAssessment of Blood Glucose Control in the Pediatric Intensive Care Unit: Extension of the Glycemic Penalty Index toward Children and Infants
Background: The glycemic penalty index (GPI) is a measure to assess blood glucose (BG) control in critically ill adult patients but needs to be adapted for children and infants. Method: The squared differences between a clinical expertise penalty function and the corresponding polynomial function are minimized for optimization purposes. The average of all penalties (individually assigned to all BG readings) represents the patient-specific GPI. Results: Penalization in the hypoglycemic range is more severe than in the hyperglycemic range as the developing brains of infants and children may be more vulnerable to hypoglycemia. Similarly, hypoglycemia is also more heavily penalized in infants than in children. Conclusions: Extending the adult GPI toward the age-specific GPI is an important methodological step. Long-term clinical studies are needed to determine the clinically acceptable GPI cut-off level.
- 1 March 2009
- Published by Elsevier in Best Practice & Research Clinical Anaesthesiology
- Vol. 23 (1) , 69-80
Towards closed-loop glycaemic control
- 1 March 2009
- Published by Elsevier in Best Practice & Research Clinical Anaesthesiology
- Vol. 23 (1) , 69-80
Towards closed-loop glycaemic control
- Open Access
- 1 November 2008
- Published by SAGE Publications in Journal of Diabetes Science and Technology
- Vol. 2 (6) , 939-947
Statistical Approach of Assessing the Reliability of Glucose Sensors: The GLYCENSIT Procedure
Background: In healthcare, patients with diabetes are instructed on how to apply intensified insulin therapy in an optimal manner. Tight blood glucose control is also performed on patients treated in the intensive care unit (ICU). Different blood glucose meters and glucose monitoring systems (GMSs) are used to achieve this goal, and some may lack reliability. Methods: The GLYCENSIT procedure is a statistical assessment tool we are proposing for evaluating the significant difference of paired glucose measurements. The performance of the GlucoDay® system in the ICU is analyzed with GLYCENSIT. Results: The GLYCENSIT analysis comprises three phases: testing possible persistent measurement behavior as a function of the glycemic range, testing the number of measurement errors with respect to a standard criterion for binary assessment of glucose sensors, and computing the tolerance intervals that indicate possible test sensor deviations for new observations. The probability of the tolerance intervals directly reflects the number of samples and additionally improves current assessment techniques. The method can be tuned according to the clinician's preferences regarding significance level, tolerance level, and glycemic range cutoff values. The measurement behavior of the GlucoDay sensor is found to be persistent but inaccurate and returns wide tolerance intervals, suggesting that the GlucoDay sensor may not be sufficiently reliable for glycemia control in the ICU. Conclusions: The GLYCENSIT procedure aims to serve as statistical guide for clinicians in the assessment of glucose sensor devices.
- 1 November 2008
- Published by SAGE Publications in Journal of Diabetes Science and Technology
- Vol. 2 (6) , 939-947
Open AccessStatistical Approach of Assessing the Reliability of Glucose Sensors: The GLYCENSIT Procedure
Background: In healthcare, patients with diabetes are instructed on how to apply intensified insulin therapy in an optimal manner. Tight blood glucose control is also performed on patients treated in the intensive care unit (ICU). Different blood glucose meters and glucose monitoring systems (GMSs) are used to achieve this goal, and some may lack reliability. Methods: The GLYCENSIT procedure is a statistical assessment tool we are proposing for evaluating the significant difference of paired glucose measurements. The performance of the GlucoDay® system in the ICU is analyzed with GLYCENSIT. Results: The GLYCENSIT analysis comprises three phases: testing possible persistent measurement behavior as a function of the glycemic range, testing the number of measurement errors with respect to a standard criterion for binary assessment of glucose sensors, and computing the tolerance intervals that indicate possible test sensor deviations for new observations. The probability of the tolerance intervals directly reflects the number of samples and additionally improves current assessment techniques. The method can be tuned according to the clinician's preferences regarding significance level, tolerance level, and glycemic range cutoff values. The measurement behavior of the GlucoDay sensor is found to be persistent but inaccurate and returns wide tolerance intervals, suggesting that the GlucoDay sensor may not be sufficiently reliable for glycemia control in the ICU. Conclusions: The GLYCENSIT procedure aims to serve as statistical guide for clinicians in the assessment of glucose sensor devices.
- Top Cited PapersOpen Access
- 26 February 2008
- Published by Springer Nature in Critical Care
- Vol. 12 (1) , R24
Glycemic penalty index for adequately assessing and comparing different blood glucose control algorithms
Introduction: Blood glucose (BG) control performed by intensive care unit (ICU) nurses is becoming standard practice for critically ill patients. New (semi-automated) 'BG control' algorithms (or 'insulin titration' algorithms) are under development, but these require stringent validation before they can replace the currently used algorithms. Existing methods for objectively comparing different insulin titration algorithms show weaknesses. In the current study, a new approach for appropriately assessing the adequacy of different algorithms is proposed. Methods: Two ICU patient populations (with different baseline characteristics) were studied, both treated with a similar 'nurse-driven' insulin titration algorithm targeting BG levels of 80 to 110 mg/dl. A new method for objectively evaluating BG deviations from normoglycemia was founded on a smooth penalty function. Next, the performance of this new evaluation tool was compared with the current standard assessment methods, on an individual as well as a population basis. Finally, the impact of four selected parameters (the average BG sampling frequency, the duration of algorithm application, the severity of disease, and the type of illness) on the performance of an insulin titration algorithm was determined by multiple regression analysis. Results: The glycemic penalty index (GPI) was proposed as a tool for assessing the overall glycemic control behavior in ICU patients. The GPI of a patient is the average of all penalties that are individually assigned to each measured BG value based on the optimized smooth penalty function. The computation of this index returns a number between 0 (no penalty) and 100 (the highest penalty). For some patients, the assessment of the BG control behavior using the traditional standard evaluation methods was different from the evaluation with GPI. Two parameters were found to have a significant impact on GPI: the BG sampling frequency and the duration of algorithm application. A higher BG sampling frequency and a longer algorithm application duration resulted in an apparently better performance, as indicated by a lower GPI. Conclusion: The GPI is an alternative method for evaluating the performance of BG control algorithms. The blood glucose sampling frequency and the duration of algorithm application should be similar when comparing algorithms.
- 26 February 2008
- Published by Springer Nature in Critical Care
- Vol. 12 (1) , R24
Top Cited PapersOpen AccessGlycemic penalty index for adequately assessing and comparing different blood glucose control algorithms
Introduction: Blood glucose (BG) control performed by intensive care unit (ICU) nurses is becoming standard practice for critically ill patients. New (semi-automated) 'BG control' algorithms (or 'insulin titration' algorithms) are under development, but these require stringent validation before they can replace the currently used algorithms. Existing methods for objectively comparing different insulin titration algorithms show weaknesses. In the current study, a new approach for appropriately assessing the adequacy of different algorithms is proposed. Methods: Two ICU patient populations (with different baseline characteristics) were studied, both treated with a similar 'nurse-driven' insulin titration algorithm targeting BG levels of 80 to 110 mg/dl. A new method for objectively evaluating BG deviations from normoglycemia was founded on a smooth penalty function. Next, the performance of this new evaluation tool was compared with the current standard assessment methods, on an individual as well as a population basis. Finally, the impact of four selected parameters (the average BG sampling frequency, the duration of algorithm application, the severity of disease, and the type of illness) on the performance of an insulin titration algorithm was determined by multiple regression analysis. Results: The glycemic penalty index (GPI) was proposed as a tool for assessing the overall glycemic control behavior in ICU patients. The GPI of a patient is the average of all penalties that are individually assigned to each measured BG value based on the optimized smooth penalty function. The computation of this index returns a number between 0 (no penalty) and 100 (the highest penalty). For some patients, the assessment of the BG control behavior using the traditional standard evaluation methods was different from the evaluation with GPI. Two parameters were found to have a significant impact on GPI: the BG sampling frequency and the duration of algorithm application. A higher BG sampling frequency and a longer algorithm application duration resulted in an apparently better performance, as indicated by a lower GPI. Conclusion: The GPI is an alternative method for evaluating the performance of BG control algorithms. The blood glucose sampling frequency and the duration of algorithm application should be similar when comparing algorithms.
- Open Access
- 1 January 2008
- Published by Springer Nature in Critical Care
- Vol. 13 (1) , 102
Ingredients for adequate evaluation of blood glucose algorithms as applied to the critically ill
The article by Eslami and colleagues provides an overview of the indicators used to measure the quality of blood glucose control in patients admitted to the intensive care unit. Each indicator can be related to one or more of the following categories: blood glucose zones, blood glucose levels, time intervals, and features of the insulin titration algorithm. Some important issues (for instance those concerning the clarity of definitions used for glycaemic thresholds) are raised. This systematic review calls for a practical guide to advise the clinician how different blood glucose signals should (ideally) be evaluated and which steps should to be undertaken.
- 1 January 2008
- Published by Springer Nature in Critical Care
- Vol. 13 (1) , 102
Open AccessIngredients for adequate evaluation of blood glucose algorithms as applied to the critically ill
The article by Eslami and colleagues provides an overview of the indicators used to measure the quality of blood glucose control in patients admitted to the intensive care unit. Each indicator can be related to one or more of the following categories: blood glucose zones, blood glucose levels, time intervals, and features of the insulin titration algorithm. Some important issues (for instance those concerning the clarity of definitions used for glycaemic thresholds) are raised. This systematic review calls for a practical guide to advise the clinician how different blood glucose signals should (ideally) be evaluated and which steps should to be undertaken.